Mack and colleagues questioned the use of CD44 as a specific CSC marker in HNSCC since CD44 was abundantly expressed in most tumor cells within HNSCC (60%-100%) and therefore could not be used to distinguish normal from benign or malignant epithelia of the head and neck [10]. This evidence concerns the gene CD44 and head and neck squamous cell carcinoma.